Turning cancer biology into better decisions.
Blood-based tumor microenvironment profiling.
BIOLOGICAL EVIDENCE
Molecular
Cellular
Clinical
Outcomes
DEVELOPMENT DECISION
A clear population, biomarker, or next-phase strategy
One tissue snapshot is not enough.
Immunotherapies and other TME-dependent drugs are often selected and evaluated on a single biopsy taken before treatment. The tumor microenvironment changes over time and under therapy, and repeat biopsies are invasive and rarely feasible. Development teams are left making decisions on a static, partial view.
A static view of a changing system
PLATFORM
One blood draw. A view of the tumor microenvironment.
01
Routine blood draw
A standard blood sample, collected at any visit.
02
Complementary molecular layers
Multiple molecular layers capture both the cellular composition of the tumor microenvironment and what those cells are doing.
03
Integrated TME state
The layers are combined into a single TME readout that no single layer provides alone, and it can be repeated at every visit.
APPLICATIONS
Built for oncology translational and clinical development teams.
BEFORE A TRIAL
Before a trial: patient selection
Characterize the tumor microenvironment across a patient population to define who is most likely to respond.
Compare baseline TME states with treatment-linked outcomes to develop a practical selection hypothesis for prospective testing.
Explore Applications
DURING A TRIAL
Track how the tumor microenvironment shifts under treatment to identify response and resistance biomarkers earlier.
Explore Applications
TOWARD DIAGNOSTICS
Translate validated TME biomarkers into a path toward companion diagnostic development.
Explore Applications
WHY CLYRA
What makes Clyra different.
Composition and activity
We read which cells are present and what they are doing, not just one or the other.
Longitudinal by design
Blood-based, so the tumor microenvironment can be measured repeatedly over the course of treatment.
Built with drug developers
Deliverables designed around trial decisions: patient selection, biomarker strategy, and next-phase design.
What decision does your program need to make?
If you are selecting patients for a TME-dependent therapy, building a biomarker strategy, or interpreting early clinical data, let’s discuss your program.